FutureTechIR

FutureTech II Acquisition Corp. is a special purpose acquisition company (SPAC) focused on the life sciences and biotechnology sectors. In late 2024, the company entered into a definitive business combination agreement with Longevity Biomedical, Inc., a biopharmaceutical firm dedicated to developing therapies that restore tissue form and function to increase human health span. The combined entity, which is expected to trade under the ticker symbol LBIO, manages a late-stage pipeline featuring an ultrasound device for ischemic stroke (LBI-201) and an injectable biomaterial for soft tissue reconstruction (LBI-101). The company aims to address significant unmet needs in neurology, ophthalmology, and regenerative medicine for the aging population.